Leukeran (chlorambucil) Coupons, Discounts & Cost
Leukeran (chlorambucil) is an alkylating cytostatic agent with antitumor activity. One way to save money on the Leukeran retail cost regardless of income and insurance status is to use Leukeran coupons or discount cards from RXCoupons. Use our Chlorambucil coupons at your online pharmacy and receive up to 75% off the sale price each time you refill your prescription.
Leukeran drug information
Leukeran (chlorambucil) is an alkylating cytostatic agent with antitumor activity. Leukeran can be taken if the patient suffers from Hodgkin's lymphoma (malignant granuloma, lymphoma), lymphosarcoma, Waldenstrom macroglobulinemia (WM), chronic lymphocytic leukemia.
Do NOT use Leukeran in the following cases:
Absolute contraindications: pregnancy, lactation (breastfeeding), hypersensitivity to any component.
Relative contraindications (the drug is used with caution due to the high risk of side effects): inhibition of bone marrow hematopoiesis (anemia, thrombocytopenia and leukopenia), chickenpox, shingles, acute infectious diseases of bacterial, viral and fungal etiology, bone marrow infiltration by the tumor cells, urolithiasis, severe kidney and liver disorders, gout, head trauma, epilepsy.
Dosage indications for Leukeran
The tablets are taken whole (do not chew or crush them). The drug is preferably used in the complex therapy, so the correct dosage regimen should be based on annotations to the drugs used in combination with Leukeran.
The recommended dosing schedule depending on the disease: Hodgkin's lymphoma (monotherapy): 0.2 mg/kg of body weight per day for 4-8 weeks; non-Hodgkin lymphoma (monotherapy): initial dose - 0.1-0.2 mg/kg of body weight per day for 4-8 weeks. Reduce the daily dose for further supportive treatment.
Chronic lymphocytic leukemia: initial dose - 0.15 mg/kg of body weight per day to reduce the total number of white blood cells to 10.000 cells/mm3. It is allowed to take maintenance dose (0.1 mg/kg of body weight per day) after 4 weeks.
Waldenstrom macroglobulinemia: initial dose - 6-12 mg a day every day; maintenance dose - 2-8 mg per day every day.
Leukeran is used in children to treat Hodgkin disease and non-Hodgkin lymphoma (use the same scheme as for adult patients). The daily dose should not exceed 0.1 mg/kg of body weight in the case of lymphocytic infiltration or hypoplasia of the bone marrow.
Possible side effects from taking Leukeran
Hematopoietic system: very often - thrombocytopenia, leukopenia, lymphopenia, decreased hemoglobin, neutropenia; rarely - depression of bone marrow function.
Gastrointestinal tract: often - ulceration of the oral mucosa, nausea, vomiting, diarrhea; rarely - toxic and allergic hepatotoxic effects (cirrhosis, jaundice, cholestasis).
Respiratory system: very rarely - interstitial pneumonia, interstitial pulmonary fibrosis (may develop in the case of long-term use of the drug).
Allergic responses: skin rash; rarely - angioedema, Stevens-Johnson syndrome (malignant exudative erythema), Lyell's syndrome (toxic epidermal necrolysis).
Nervous system: often - muscle cramps in nephrotic syndrome (in children); rarely - generalized or local seizures in adults and children taking chlorambucil daily (therapeutic dose or high-dose pulse therapy), tremor, muscle twitching, paresis, peripheral neuropathy, agitation, severe weakness, confusion, anxiety, hallucinations.
Urinary system: very rarely - aseptic cystitis.
Other reactions: hyperuricemia, hyperthermia or nephropathy due to increased formation of uric acid, secondary amenorrhea, irregular menstruation, secondary malignancy, azoospermia.
Overdose symptoms include: ataxia, irritability, reversible pancytopenia, recurrent epileptic seizures.
Special instructions when taking Leukeran
Leukeran is a cytotoxic agent that is used only under the supervision of a specialist. Since chlorambucil can inhibit bone marrow function, patients should regularly plan a complete blood count (at least 2-3 times per week). At therapeutic doses, the drug inhibits the production of lymphocytes and influences the level of hemoglobin (to a lesser extent). It must be remembered that the number of neutrophils can be reduced for more than 10 days after the last dose.
Leukeran can be used not earlier than after 1-2 months after completion of radiotherapy or treatment with cytostatic agents (if there are no signs of severe leucopenia, anemia and thrombocytopenia).
The following groups of patients should be under close medical supervision because of the high risk of seizures during the treatment: patients receiving high-dose pulse therapy with Leukeran, children with nephritic syndrome and patients with preexisting seizure disorders.